{
    "nct_id": "NCT03398135",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis",
    "inclusion_criteria": "- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.\n* Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.\n* Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.",
    "miscellaneous_criteria": ""
}